multiple sclerosis

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

By MedXY 10/10/2025

In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.

Allergy & Immunology Clinical Updates news OB/GYN & Women's Health Specialties

Menopause and Multiple Sclerosis: Evaluating the Impact on Disability Progression

By MedXY 09/29/2025

A comprehensive analysis reveals that menopause does not significantly alter the risk of disability progression in women with relapse-onset multiple sclerosis, underscoring the complexity of reproductive aging's role in disease trajectory.

Allergy & Immunology Clinical Updates OB/GYN & Women's Health

Pregnancy and Disease Outcomes in Women with Moderate to Severe Multiple Sclerosis Disability

By MedXY 09/24/2025

This study evaluates how pregnancy affects relapse rates and long-term disability in women with moderate to severe multiple sclerosis (MS), showing pregnancy reduces relapse during gestation without worsening long-term disability progression.

Allergy & Immunology news Rheumatology Specialties

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression: Insights from the BENEFIT Study

By MedXY 08/20/2025

Higher baseline serum alpha-linolenic acid levels predict reduced multiple sclerosis activity, relapses, and disability progression up to 11 years post clinical onset in a large prospective study.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Therapeutic Strategies for Disease-Modifying Therapy Management in Pregnant Women With Multiple Sclerosis: Relapse Risk and Clinical Implications

By MedXY 08/04/2025

Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.

Clinical Updates Medical News Rheumatology Specialties

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

By MedXY 08/02/2025

Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.